Pertuzumab
VIDEO: ‘Real world’ data for patients with HER2-positive, BRCA1/2 breast cancer
In this video, Elias Obeid, MD, MPH, discussed treatment patterns and clinical outcomes of patients with germline BRCA1/2-mutated, HER2-positive advanced breast cancer.
Top in hem/onc: Repurposing cancer drugs for COVID-19, Phesgo approval
Many anticancer drugs — including BTK inhibitors, JAK inhibitors, immunomodulatory drugs, and more — are being investigated as potential COVID-19 treatments. An overview of these investigations was the top story in hematology/oncology last week.
FDA approves Phesgo, at-home treatment regimen for breast cancer
The FDA today approved Phesgo, the combination of pertuzumab, trastuzumab and hyaluronidase-zzxf, for the treatment of adults with HER2-positive breast cancer.
Margetuximab holds promise in metastatic HER2-positive breast cancer
Following the promising findings of the second interim analysis of the randomized phase 3 SOPHIA trial — presented at San Antonio Breast Cancer Symposium in December 2019 — the manufacturer of the investigational agent, margetuximab, submitted a biologics license application for use in patients with metastatic HER2-positive breast cancer.